IN8BIO, INC. (INAB) Form 10-Q — Aug 6, 2026
IN8bio's Q2 2026 10-Q carries explicit going-concern language: the clinical-stage biotech held $18.0 million in cash as of June 30, 2026, which management says is not anticipated to fund projected operating expenses for at least 12 months, providing runway only through April 2027. Management is relying on pipeline prioritization, new capital raises, and potential strategic collaborations to remain funded. Net loss was $4.8 million for the quarter and $9.9 million for the first half of 2026, modestly improved from $10.6 million a year ago, with R&D and G&A each running around $5.1 million for the half.
Key figures
- Total Assets
- 21745000
- Cash Position
- 17956000
- Shares Outstanding
- 9858383
- Cash runway
- through April 2027
- Eps h1 2026
- -$0.51 (vs -$3.65 H1 2025, post reverse split)
- Long term debt
- none
- Shelf capacity
- $200.0 million (Form S-3 effective May 20, 2026)
- Net loss h1 2026
- -$9.87 million (vs -$10.64 million H1 2025)
- Net loss q2 2026
- -$4.78 million (vs -$5.09 million Q2 2025)
- Ga expense h1 2026
- $5.10 million
- Rd expense h1 2026
- $5.11 million
- Accumulated deficit
- $151.0 million
- Reverse split ratio
- 1-for-30 (June 5, 2025)
- Atm program remaining
- $2.8 million (JonesTrading)
- Fixed lease obligations
- $2.5 million ($1.3 million within 12 months)
- Weighted avg shares q2 2026
- 19467091
- Net cash used in operating h1 2026
- $8.69 million
- Series b warrant potential proceeds
- $2.3 million (166,964 warrants at $13.50)
- Series c warrant potential proceeds
- $6.7 million (828,863 warrants at $8.10)
- Potential milestone second closing proceeds
- $20.1 million for up to 14,579,706 shares
- Aggregate gross proceeds raised since inception
- $163.2 million
Price after filing
Close on the filing date to close N calendar days later (from $0.96). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.